Esophageal Cancer - Pipeline Insight, 2024

This “Esophageal Cancer- Pipeline Insight, 2024” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Esophageal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Esophageal Cancer: Understanding

Esophageal Cancer: Overview

Esophageal cancer develops in the esophagus, which is the tube that connects throat to the stomach. Tumors arise in the mucosa, which is the inner lining of the esophagus. There are two types of esophageal cancer, each with different risk factors: Adenocarcinoma -Cancers that start in gland cells at the bottom of the esophagus are called adenocarcinomas. This type of cancer is the most common esophageal cancer. It usually occurs closer to the stomach. Chronic acid reflux, gastroesophageal reflux disease (GERD), Barrett’s esophagus and chronic heartburn can increase the risk of developing adenocarcinoma esophageal cancer. Squamous Cell Carcinoma- This type of esophageal cancer arises from squamous cells that are primarily in the upper esophagus. Squamous cell tumors are associated with heavy alcohol consumption, smoking and organ transplants. Factors that can increase the risk of esophageal cancer include: Smoking, heavy alcohol consumption, chronic heartburn or acid reflux, gastroesophageal reflux disease (GERD), barrett’s esophagus, a condition that sometimes develops in people with GERD and Achalasia, a rare disorder of muscles in the lower esophagus. Most esophageal cancer symptoms aren’t noticeable until the cancer is in an advanced stage when it may be hard to treat. Symptoms of esophageal cancer may be caused by other, more common conditions. The most common symptom of esophageal cancer is trouble swallowing, especially a feeling of food stuck in the chest. With some patients, choking on food also occurs. These symptoms gradually worsen over time, with an increase in pain when swallowing, as esophagus narrows from the growing cancer. If the person suffer from chronic heartburn or gastroesophageal reflux disease (GERD), person would already be familiar with a pain that feels like burning in the middle of the chest. That painful sensation may become more noticeable when esophageal cancer develops. Developing a hoarse, scratchy voice or a cough that doesn’t go away can also indicate the presence of esophageal cancer. Esophageal cancer is often not diagnosed until it reaches advanced stages, so accuracy in the diagnosis and staging process is especially crucial for the best possible outcome. A gastroenterologist (a doctor who specializes in diseases of the digestive system) may be the first provider to recognize the signs of esophageal cancer. There are several types of tests to diagnose esophageal cancer. The most common tests are: Endoscopy with biopsy: Sometimes called an esophagogastroduodenoscopy or EGD, this is the most common test a doctor will perform to test for esophageal cancer. Endoscopic ultrasonography: If the biopsy results reveal cancer, doctor may order an endoscopic ultrasound (EUS). This is one of the most accurate imaging procedures for detecting esophageal cancer. Treatment for esophageal cancer is individualized to each patient’s unique needs. Treatment options include: Radiation therapy: The use of X-rays, gamma rays and charged particles to fight cancer, Chemotherapy: The use of anticancer drugs to treat cancerous cells and Surgery: The use of an operation to remove the cancerous tissue from the body.

“Esophageal Cancer- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Esophageal Cancer pipeline landscape is provided which includes the disease overview and Esophageal Cancer treatment guidelines. The assessment part of the report embraces, in depth Esophageal Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Esophageal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Esophageal Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Esophageal Cancer.

Esophageal Cancer Emerging Drugs Chapters

This segment of the Esophageal Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Esophageal Cancer Emerging Drugs

AN-0025: Adlai NortyeAN0025 is a clinical stage, potential first-in-class EP4 antagonist designed to modulate tumor microenvironment. It blocks the PGE2-EP4 signaling pathway to inhibit PGE2-mediated immunosuppression in the tumor microenvironment. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Esophageal Cancer.

Tucatinib: SeagenTucatinib (TUKYSA®) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein, a protein that contributes to cancer cell growth.HER2 is overexpressed in multiple cancers, including breast, colorectal, and gastric cancers. In preclinical in vitro studies, TUKYSA inhibited phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell growth (proliferation), and showed anti-tumor activity in HER2-expressing tumor cells. In preclinical and clinical studies, TUKYSA inhibited the growth of HER2-expressing tumors. The combination of TUKYSA and the anti-HER2 antibody trastuzumab has also been shown to increase anti-tumor activity in vitro and in vivo compared to either medicine alone. Currently, the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Esophageal Cancer.

APX 005M: ApexigenAPX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. APX005M targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. Binding of APX005M to CD40 on antigen presenting cells (i.e., dendritic cells, monocytes and B-cells) initiates a multi-faceted immune response bringing multiple components of the immune system (e.g., T cells, macrophages) to work in concert against cancer. APX005M is currently in Phase 2 clinical development for the treatment of cancers such as pancreatic cancer, esophageal and gastroesophageal junction cancers, melanoma, non-small cell lung cancer, rectal cancer and sarcoma in various combinations with immunotherapy, chemotherapy, radiation therapy or a cancer vaccine.

Esophageal Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Esophageal Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Esophageal Cancer

There are approx. 80+ key companies which are developing the therapies for Esophageal Cancer. The companies which have their Esophageal Cancer drug candidates in the most advanced stage, i.e. phase II/III include, Seagen.

Phases

This report covers around 80+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Esophageal Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Esophageal Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Esophageal Cancer drugs.

Esophageal Cancer Report Insights

• Esophageal Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Esophageal Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Esophageal Cancer drugs?
• How many Esophageal Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Esophageal Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Esophageal Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Esophageal Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• BeiGene
• AstraZeneca
• CSPC ZhongQi Pharmaceutical Technology
• Amgen
• Jiangsu Hengrui Medicine
• Oncolys Biopharma
• Pfizer
• Novartis
• Luye Pharma
• Eli Lilly and Company
• ImmunoFrontier, Inc
• Adaptimmune
• Innovent Biologics (Suzhou) Co. Ltd.
• Genentech
• Janssen Pharmaceuticals
• Merck KGaA
• Shenzhen Hornetcorn Biotechnology
• Apexigen, Inc.
• Highlight Therapeutics
• EMD Serono
• HaiHe Biopharma
• Lumicell
• Jacobio Pharmaceuticals Co., Ltd.
• TESARO
• Ascentage Pharma Group Inc.,
• Adlai Nortye
• Seagen

Key Products

• AN-0025
• Tucatinib
• APX 005M
• Tislelizumab
• Durvalumab
• Mitoxantrone liposomal
• Panitumumab
• SHR-1210
• OBP-301
• Apatinib
• Sunitinib malate
• RAD001
• Irinotecan
• Ramucirumab
• IMF-001
• Autologous genetically modified ADP-A2M4CD8 cells
• Sintilimab
• Atezolizumab
• Erdafitinib
• M6620
• DC-CIK
• APX005M
• BO-112
• M1231
• Ramucirumab
• CYH33

This product will be delivered within 1-3 business days.